Compare GBIO & GRF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GBIO | GRF |
|---|---|---|
| Founded | 2016 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.3M | 42.5M |
| IPO Year | 2020 | N/A |
| Metric | GBIO | GRF |
|---|---|---|
| Price | $5.66 | $10.80 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $8.88 | N/A |
| AVG Volume (30 Days) | ★ 93.6K | 3.0K |
| Earning Date | 03-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.70% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.16 |
| Revenue | ★ $15,270,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $8.15 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.00 | $7.93 |
| 52 Week High | $9.25 | $10.19 |
| Indicator | GBIO | GRF |
|---|---|---|
| Relative Strength Index (RSI) | 54.81 | 51.09 |
| Support Level | $5.41 | $10.71 |
| Resistance Level | $5.72 | $10.98 |
| Average True Range (ATR) | 0.13 | 0.15 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 78.38 | 51.39 |
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.
Eagle Capital Growth Fund Inc is a diversified closed-end investment company. The fund's objective is long-term growth utilizing the concept of total return for selecting investments. It seeks to achieve its investment objectives by investing predominantly in U.S. issuer common stock by giving preference to high-quality companies, where high quality denotes substantial operating income margins, high returns on capital, and robust balance sheets.